Equities

Jacobio Pharmaceuticals Group Co Ltd

Jacobio Pharmaceuticals Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.86
  • Today's Change-0.10 / -5.10%
  • Shares traded924.90k
  • 1 Year change-71.73%
  • Beta1.0562
Data delayed at least 15 minutes, as of May 03 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jacobio Pharmaceuticals Group Co Ltd is a China-based investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly conducts business within the domestic market.

  • Revenue in HKD (TTM)68.63m
  • Net income in HKD-388.03m
  • Incorporated2018
  • Employees301.00
  • Location
    Jacobio Pharmaceuticals Group Co LtdBuilding F2, No. 88Kechuang 6th Street, Beijing EconomicTechnological Development AreaBEIJING ChinaCHN
  • Phone+86 1 056315466
  • Fax+86 1 056315314
  • Websitehttp://www.jacobiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Brii Biosciences Ltd666.67k-188.90m999.61m128.00--0.2965--1,499.41-0.2597-0.25970.00094.620.0002----5,208.33-5.60---5.84-------29,881.69------0.001---98.80--63.90------
Zhongzhi Pharmaceutical Holdings Ltd2.21bn175.88m1.02bn2.64k5.680.89953.540.46010.20770.20772.611.311.122.5310.54837,992.408.957.6914.1511.7559.7360.568.016.730.894--0.142442.4612.2612.4153.0013.8617.653.22
Jacobson Pharma Corporation Ltd1.68bn212.16m1.14bn1.59k5.120.47792.880.67740.11120.14090.88221.190.37222.877.50940,829.505.164.916.616.6042.0541.8113.8514.321.015.620.364635.9711.912.8941.304.42-6.226.39
VIVA Biotech Holdings2.33bn-125.46m1.32bn2.08k--0.327910.910.5661-0.0638-0.06381.201.860.28054.845.131,121,374.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.150.0350.3412---9.4259.3178.03------
TOT Biopharm International Co Ltd843.47m-40.80m1.34bn463.00--1.81354.651.59-0.0563-0.05631.160.96010.58081.877.75---2.81-20.01-3.72-25.2173.5374.74-4.84-68.531.48-4.600.3348--76.5481.8824.36------
Essex Bio-Technology Ltd1.71bn275.26m1.35bn1.48k5.080.70224.030.79150.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
CStone Pharmaceuticals501.18m-396.79m1.40bn230.00--2.84--2.79-0.3146-0.31460.39680.38440.28112.443.722,179,041.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
Ascletis Pharma Inc61.15m-156.36m1.42bn219.00--0.5935--23.19-0.1469-0.14690.05692.360.0222.303.86279,231.80-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04------
Wuhan YZY Biopharma Co Ltd-100.00bn-100.00bn1.44bn123.00-----------------------------------------------------1.50------
Jacobio Pharmaceuticals Group Co Ltd68.63m-388.03m1.55bn301.00--1.34--22.61-0.5019-0.50190.08881.460.0419--5.21228,017.00-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43--19.18--
Mabpharm Ltd94.18m-226.21m1.63bn347.00--7.35--17.30-0.0549-0.05490.02280.05370.08930.11766.02271,403.80-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
Hua Medicine82.78m-228.24m1.70bn177.00--14.42--20.53-0.2335-0.23350.08470.11170.05381.691.98467,665.60-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80------
Immunotech Biopharm Ltd0.00-361.77m1.75bn210.00--9.33-----0.703-0.7030.000.36460.00----0.00-38.88-37.42-50.88-45.48--------1.03-1.970.4327-------5.25------
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn352.24m1.76bn1.14k4.990.56913.881.410.23430.23430.82782.060.31562.316.371,088,196.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
Acotec Scientific Holdings Ltd511.99m15.65m2.06bn638.00126.401.4731.424.030.05210.05211.704.470.31360.72133.44802,493.600.9589--1.03--79.65--3.06--9.122.750.1529--19.80---79.35------
SinoMab Bioscience Ltd1.47m-262.68m2.07bn233.00--6.16--1,406.45-0.258-0.2580.00150.30860.0015-------26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---8.150.604------14.45------
Data as of May 03 2024. Currency figures normalised to Jacobio Pharmaceuticals Group Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.01%Per cent of shares held by top holders
HolderShares% Held
Hillhouse Investment Management Ltd. (Hong Kong)as of 29 Dec 202347.44m5.99%
The Vanguard Group, Inc.as of 05 Apr 202413.79m1.74%
E Fund Management Co., Ltd.as of 30 Jun 202311.87m1.50%
Penghua Fund Management Co., Ltd.as of 30 Jun 20235.04m0.64%
Bosera Asset Management Co., Ltd.as of 31 Dec 20223.31m0.42%
HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 20232.43m0.31%
BlackRock Advisors (UK) Ltd.as of 02 Apr 20241.49m0.19%
Dimensional Fund Advisors LPas of 04 Apr 2024795.90k0.10%
HuaAn Fund Management Co., Ltd.as of 30 Jun 2023612.60k0.08%
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2023379.20k0.05%
More ▼
Data from 30 Jun 2023 - 22 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.